TARS
$69.79
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States.
Recent News
Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Mixed Share Performance
Tarsus Pharmaceuticals overview after recent share performance Tarsus Pharmaceuticals (TARS) has seen mixed share performance recently, with a decline over the past 3 months but a gain over the past month. This has prompted fresh attention on its valuation and business profile. See our latest analysis for Tarsus Pharmaceuticals. At a share price of $73.26, Tarsus Pharmaceuticals reflects mixed recent momentum, with a 13.37% 1 month share price return contrasting with a weaker year to date...
Oppenheimer Raises Its Price Target on Tarsus Pharmaceuticals, Inc. (TARS) to $105 and Maintains an Outperform Rating
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) is among the 10 Fastest Growing NASDAQ Stocks to Buy. On February 25, 2026, Oppenheimer analyst Andreas Argyrides raised the firm’s price target on Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) to $105 from $95 and maintained an Outperform rating following quarterly results. Management also provided first-time FY26 net product sales guidance of $670M–$700M […]
Maker Of Eye Drops Has Sights On Buy Point
This eye drops stock is building a cup base following the biopharmaceuticals earnings report. Wall Street sees profit on its horizon.
These Growth Stocks Form Classic Cup Bases. Here's Where To Buy.
Two eyedrops stocks are forming cup bases on their charts and one has earnings coming up. A data center play is in a cup base buy zone.
Has The Market Rerated Tarsus Pharmaceuticals (TARS) Too Cautiously After XDEMVY Adoption Headlines?
If you are wondering whether Tarsus Pharmaceuticals is still attractively priced after its recent run, this article will walk through what the current share price could imply about value. The stock last closed at US$72.65, with returns of 14.8% over 7 days, 6.9% over 30 days, a 10.1% decline year to date, 70.7% over 1 year and a very large gain over 3 years that is well above 7x. Recent price moves have come alongside heightened attention on the company's lead asset and its potential market,...